Research-based PAM50 signature and long-term breast cancer survival

MiRNAs and long-term breast cancer survival: Evidence from the WHEL Study

(2019) Loki Natarajan et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

(2018) Ivana Sestak et al.   JAMA Oncology

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics

(2017) Kay Dias et al.   PLoS One

Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer

(2016) Emad A Rakha et al.   HISTOPATHOLOGY

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

(2016) Richard Buus et al.   JNCI-Journal of the National Cancer Institute

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

(2015) Brett Wallden et al.   BMC Medical Genomics

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

(2014) Torsten Nielsen et al.   BMC CANCER

EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer

(2014) François Bertucci et al.   CANCER LETTERS

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

(2011) Gong Tang et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

(2011) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Practical implications of gene-expression-based assays for breast oncologists

(2011) Aleix Prat et al.   Nature Reviews Clinical Oncology

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene

(2010) F M Buffa et al.   BRITISH JOURNAL OF CANCER

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer

(2009) L. Natarajan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

A compact VEGF signature associated with distant metastases and poor outcomes

(2009) Zhiyuan Hu et al.   BMC Medicine

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY